Leronlimab will b approved by FDA because Remdesivir was approved
for emergency use in USA (plus approved in Japan for severe CV)
and all the preliminary data shows Leronlimab is
far more effective than Remdesivir across the spectrum from
mild , moderate to severe CV-19.

The FDA will set the bar a low as possible for use of a widespread
treatment showing some effectiveness especially in the case of Leronlimab
because it already has a PROVEN SAFETY profile given the
800+ patients who have taken it thru HIV studies.

So IMO when the first results come out in JULY from the
P2 trial thats when CYDY the stock blasts higher to never
before seen levels.